Evaluation of cationized rat albumin as a potential bloodbrain barrier drug transport vector
Despite decades of work, the precise receptor and mechanism are still not fully established
Matis has been involved in translational research, helping bridge the gap between scientific discovery and patient care
The research peptide market remains largely unregulated, creating opportunities for contamination, underdosing, and outright substitution
The peptide stacking guide covers similar principles about responding to your body rather than following rigid timelines
Who Should Consider GLP-1 Therapy FDA indications for weight loss require: BMI 30 (obesity), or BMI 27 (overweight) with at least one weight-related condition hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or similar These thresholds set eligibility, but they don't answer the more important question: who benefits most